About Immunovent
Immunovent is a Healthcare company based in New York (United States) founded in 2012. It operates as a diagnostic tests for allergies are developed using mucosal brush samples. Immunovent offers products and services including LAMB-Dx. Its focus areas include Life Sciences, Immunology, In Vitro Diagnostic Tests and Allergies. Its legal entity is Immunovent, LLC. Its competitors include Allergy Amulet, YorkTest, Microtest Diagnostics, ATANIS Biotech and DST and 3 more; 3 of its 8 listed competitors have raised funding.
Company details
Immunovent was founded in 2012 and is based in New York, United States, within the biotechnology sector. Diagnostic tests for allergies are created, focusing on the Local Antibody Mucosal Brush Diagnostic (LAMB-Dx) assay. IgE immunoglobulins are detected in epithelial cell samples obtained from the nose or mouth. Proof-of-concept studies have been finished, with the initial test anticipated for release in late 2016 or early 2017.
- Headquarters New York, United States
- SectorsHealthcare
- Website immunovent.com
- Social LinkedIn X
- Legal Name Immunovent, Llc
Products & Services of Immunovent
Immunovent offers a comprehensive portfolio of products and services, including LAMB-Dx.
Detects allergies via mucosal brush for rapid and safe diagnosis.
Competitors of Immunovent
Immunovent has 8 listed competitors in our database, 3 of them funded. They include Allergy Amulet, YorkTest, Microtest Diagnostics, ATANIS Biotech and DST, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| allergyamulet.com | 2016 | Madison, United States | $12.57M | – | Portable food allergen sensors are offered via an online platform. | |
| yorktest.com | 1982 | York, United Kingdom | $12.03M | 38 | At-home food and allergy test kits are developed by YorkTest. | |
| microtestdx.com | 2002 | London, United Kingdom | $2.5M | 6 | Functions as an automated allergy testing service. | |
| atanis-biotech.com | 2021 | Sursee, Switzerland | – | – | Developer of a cell-based assay for the diagnosis of allergies | |
| dst-diagnostic.com | 2005 | Schwerin, Germany | – | 42 | Innovative in-vitro diagnostic solutions are developed by DST. | |
| macroarraydx.com.ua | 2016 | Kiev, Ukraine | – | – | Allergen analyzers are provided for in-vitro IgE level determination. | |
| allergenis.com | 2017 | Hatfield, United States | – | – | Develops accurate allergy testing solutions for healthcare providers and patients. | |
| bangqibio.tcc.mode | 2020 | Suzhou, China | – | – | Instruments and reagents for immune disorder diagnosis are developed. |
Detailed competitors of Immunovent
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Immunovent (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Immunovent
Immunovent was founded in 2012.
Immunovent is headquartered in New York, United States. It is registered at New York, New York, United States.
Immunovent was founded in 2012 and is based in New York, United States, within the biotechnology sector. Diagnostic tests for allergies are created, focusing on the Local Antibody Mucosal Brush Diagnostic (LAMB-Dx) assay. IgE immunoglobulins are detected in epithelial cell samples obtained from the nose or mouth. Proof-of-concept studies have been finished, with the initial test anticipated for release in late 2016 or early 2017.
Immunovent's top competitors include Allergy Amulet, ATANIS Biotech and YorkTest.
Immunovent offers LAMB-Dx.
Immunovent operates through Immunovent, Llc.